Latest data from May 6, 2022
Number of Health Center respondents = 17 (63% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 1,738 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 47.58% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 155 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 41.43% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 46.03% | 52.90% |
| White, Hispanic/Latino Patients | 15.19% | 18.71% |
| Black/African American, Non-Hispanic/Latino Patients | 16.11% | 13.55% |
| Black/African American, Hispanic/Latino Patients | 0.35% | 0.00% |
| Asian Patients3 | 4.32% | 0.00% |
| American Indian/Alaska Native Patients3 | 0.17% | 0.00% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.17% | 0.00% |
| Patients with More Than One Race3 | 1.50% | 1.29% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 3.97% | 3.87% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 1.67% | 1.29% |
| Unreported/Refused to Report Race and Ethnicity | 10.53% | 8.39% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 410 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 71.17% |
| COVID-19 Immunization Series Completed | 528 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 61.07% |
| COVID-19 Immunization Series Additional | 803 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 62.47% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 27.56% | 35.98% | 37.11% |
| White, Hispanic/Latino Patients | 23.41% | 13.64% | 12.95% |
| Black/African American, Non-Hispanic/Latino Patients | 23.66% | 17.61% | 27.52% |
| Black/African American, Hispanic/Latino Patients | 0.49% | 0.57% | 0.37% |
| Asian Patients3 | 2.68% | 4.36% | 1.99% |
| American Indian/Alaska Native Patients3 | 0.00% | 0.38% | 1.00% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.24% | 1.89% | 0.62% |
| Patients with More Than One Race3 | 5.37% | 3.41% | 4.23% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 12.20% | 14.58% | 13.08% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.73% | 1.70% | 0.75% |
| Unreported/Refused to Report Race and Ethnicity | 3.66% | 5.87% | 0.37% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 35.29% |
| 1 to 24 Hours | 29.41% |
| More Than 24 Hours | 29.41% |
| N/A | 5.88% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 5.88% |
| Staffing to administer the vaccine | 29.41% |
| Vaccine confidence | 47.06% |
| Vaccine storage capacity | 5.88% |
| Vaccine supply | 0.00% |
| Other | 11.76% |
| None | 29.41% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 29.41% |
| Average Percent of Health Center Visits Conducted Virtually | 7.06% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 23.53% |
| Number of Mobile Van Sites | 0 |
| Number of Pop-up Clinics | 15 |
| Number of School-Based Vaccination Sites | 0 |
| Number of Family Vaccination Clinics | 28 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 5.88% |
| Refer patients to another organization that provides monoclonal antibody therapies | 52.94% |
| None | 41.18% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 11.76% |
| Patient awareness/education | 5.88% |
| Staffing capacity | 17.65% |
| Therapy administration/onsite logistics | 17.65% |
| Other | 5.88% |
| None | 58.82% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 12 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 7,732 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provided to Existing Health Center Patients | 83.33% |
| Provided to General Public Who Came to the Health Center | 50.00% |
| Provided at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 16.67% |
| Provided at Other Community Events | 58.33% |
| Provided to migratory/seasonal agricultural workers directly or through partnerships with community organizations serving these individuals | 8.33% |
| Provided to individuals with limited English proficiency directly or through partnerships with community organizations serving these individuals | 8.33% |
| Provided to older adults and/or individuals with disabilities directly or through partnerships with community organizations serving these individuals | 16.67% |
| Provided to school-age children and/or their families directly or through partnerships with schools | 16.67% |
| Provided to individuals living in HUD-assisted housing and/or individuals experiencing homelessness directly or through partnerships with local housing authorities | 16.67% |
| Other | 8.33% |
N95 Mask Distribution
| Metrics | Value |
|---|---|
| Health Centers that Distributed N95 Masks Received through the HRSA Health Center COVID-19 N95 Mask Program | 9 |
| Number of N95 Masks Distributed through the HRSA Health Center COVID-19 N95 Mask Program | 2,623 |
N95 Mask Distribution Methods5
| Metrics | Value |
|---|---|
| Provided to Existing Health Center Patients | 77.78% |
| Provided to General Public Who Came to the Health Center | 66.67% |
| Provided at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 22.22% |
| Provided at Other Community Events | 44.44% |
| Provided to migratory/seasonal agricultural workers directly or through partnerships with community organizations serving these individuals | 0.00% |
| Provided to individuals with limited English proficiency directly or through partnerships with community organizations serving these individuals | 11.11% |
| Provided to older adults and/or individuals with disabilities directly or through partnerships with community organizations serving these individuals | 22.22% |
| Provided to school-age children and/or their families directly or through partnerships with schools | 33.33% |
| Provided to individuals living in HUD-assisted housing and/or individuals experiencing homelessness directly or through partnerships with local housing authorities | 0.00% |
| Other | 11.11% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 1 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication | 8.33% |
Oral Antiviral Medication Distribution by Race and Ethnicity
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | 83.33% |
| White, Hispanic/Latino Patients | 0.00% |
| Black/African American, Non-Hispanic/Latino Patients | 0.00% |
| Black/African American, Hispanic/Latino Patients | 0.00% |
| Asian Patients3 | 0.00% |
| American Indian/Alaska Native Patients3 | 8.33% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.00% |
| Patients with More Than One Race3 | 0.00% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.00% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.00% |
| Unreported/Refused to Report Race and Ethnicity | 8.33% |
Oral Antiviral Medication Distribution by Population Type
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | 0.00% |
| Patients Experiencing Homelessness | 0.00% |
| Patients Who Are Residents of Public Housing | 0.00% |
| Patients with Limited English Proficiency | 0.00% |
| Children Under 18 Years of Age | 0.00% |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed N95 masks received through the HRSA Health Center COVID-19 N95 Mask Program as the denominator.
